Skip to content

THERAtRAME

Active
Public limited company·Scientific research and development· 4 yrs active
Avenue de l'Hôpital 1 ·4000 Liège, Belgium

THERAtRAME has been active since 2022 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €1.75M and a net result of €-2.12M. Equity is shrinking by ~2.7% per year across the filed fiscal years. Its solvency ranks better than 30% of 43 sector peers (fiscal year 2024). The computed 12-month bankruptcy probability is 1.1% (low).

KBO/BCE: BE 0786.448.581
Watch Print / PDF

Credit risk

Bankruptcy probability (12 mo)

1.1% Low
0%0,5%1,5%4%10%≥25%

How do we compute this?

Credit advice

verdict per amount and term

Timeline

What happened to this company, by date

Next filing fiscal year 2026 expected by 31-07-2027

2026
09-07-2026 NBB filing Annual accounts filed
fiscal year 2025 · full schema
29-05-2026 State Gazette act Open capture
Notarial deed · General meeting · Auditor waiver · Capital increase
2025
22-12-2025 State Gazette act Capital & shares
v3.2
23-10-2025 State Gazette act Capital & shares
v3.2
21-08-2025 NBB filing Annual accounts filed
fiscal year 2024 · full schema
09-07-2025 State Gazette act Director changes
v3.2
2024
26-06-2024 NBB filing Annual accounts filed
fiscal year 2023 · full schema
23-04-2024 State Gazette act Director changes
v3.2
2022
03-08-2022 State Gazette act Statutes amendment
v3.2
25-05-2022 State Gazette act Incorporation
oprichting

Financials

TurnoverNot included in this filing
EBIT marginNot included in this filing
Net result€-2.12M-97.6%
2023: €-1.12M 2024: €-1.07M
Working capital€1.76M+78.6%
2023: €1.75M 2024: €988k

Figures by fiscal year

fiscal year 2025 · full schema
€-3.00M€-2.00M€-1.00M€0Operating result 2023: €-2.09M€-2.09MNet result 2023: €-1.12M€-1.12MOperating result 2024: €-2.01M€-2.01MNet result 2024: €-1.07M€-1.07MOperating result 2025: €-2.62M€-2.62MNet result 2025: €-2.12M€-2.12M202320242025
Operating resultNet result
Sector comparison
Fiscal year 2024 · NACE 72, Scientific research and development · compared within the same schema type (full schema)
Metric This company Sector median Position in the sector
Solvency 35.0% 53.3%
better than 30% of 43 sector peers
Net result €-1.07M €-19k
better than 20% of 42 sector peers
Equity €775k €685k
better than 54% of 43 sector peers
Gross operating margin €7k €7k
better than 50% of 33 sector peers
Staff costs €494k €723k
higher than 30% of 30 sector peers
EBITDA
€-1.62M
-232.7% 23-25
Cash flow
€-1.12M
- 23-25
Total assets
€2.67M
+20.3% 23-25
Equity
€1.75M
+126.3% 23-25
Employees (FTE)
10
+40.3% 23-25
Staff costs
€752k
+52.3% 23-25
Income taxes
€-30k
+49.1% 23-25
Debt
€913k
-36.7% 23-25
Debt ≤ 1y
€599k
-22.8% 23-25
Debt > 1y
€290k
-55.6% 23-25
Current ratio
3.95
+73.6% 23-25
Quick ratio
3.95
+73.6% 23-25
Solvency
65.8%
+88.1% 23-25
Debt / equity
0.52
-72.0% 23-25
ROE
-120.9%
+12.7% 23-25
ROA
-79.5%
-64.2% 23-25
Interest coverage
-13.42
+68.6% 23-25
Figures by fiscal year and ratios
Fiscal year2025
Depositfull schema
Revenue-
EBITDA€-1.62M
Net profit€-2.12M
Cash flow€-1.12M
Staff costs€752k
Income taxes€-30k
Dividends-
Total assets€2.67M
Equity€1.75M
Debt€913k
of which ≤ 1y€599k
of which > 1y€290k
Working capital€1.76M
Employees (FTE)10.1
Ratios (computed)
2025
Current ratio3.95
Quick ratio3.95
Working capital ratio66.2%
Solvency65.8%
Debt / equity0.52
Long-term debt ratio0.17
Interest coverage-13.42
Gross margin-
Net margin-
ROA-79.5%
ROE-120.9%
EBITDA margin-
Days sales outstanding-
Days payable outstanding-
Inventory turnover-
Days inventory (DSI)-
This table shows the latest fiscal year. 2 prior years, with figures and ratios, belong to a paid plan. See plans →
Balance-sheet composition 2025
Full annual accounts (23 line items)
Filed balance sheet and income statement, exactly as deposited with the NBB.
Line item Code2025
Balance sheet, Assets
TOTAL ASSETS 20/58€2.67M
Fixed assets 21/28€303k
Intangible fixed assets 21€155k
Tangible fixed assets 22/27€149k
Current assets 29/58€2.36M
Amounts receivable within one year 40/41€577k
Cash & bank 54/58€1.56M
Balance sheet, Equity & liabilities
TOTAL EQUITY & LIABILITIES 10/49€2.67M
Equity 10/15€1.75M
Contributions / capital 10/11€2.48M
Accumulated profits (losses) 14€-723k
Amounts payable 17/49€913k
Amounts payable after one year 17€290k
Amounts payable within one year 42/48€599k
Trade debts payable within one year 44€460k
Income statement
Gross operating margin 9900€-869k
Operating result 9901€-2.62M
Financial income 75€595k
Financial charges 65€121k
Result before taxes 9903€-2.15M
Income taxes 67/77€-30k
Net result for the period 9904€-2.12M
Result to be appropriated 9905€-2.12M

Signals

2 signals
Persistent losses
Two consecutive loss-making years (2023 and 2024); equity fell accordingly. May indicate structural pressure on profitability.
View the result trend
Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 09-07-2026, 22 days ahead of the deadline.
No strikeouts found in the KBO publications · how complete this is
No strikeouts found in the KBO publications we processed. That series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
Filing history by fiscal year and how the deadline is computed
Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 09-07-2026, 22 days ahead of the deadline.
The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
How we compute the deadline
The year end is derived from 3 filed financial years, each closing on 31-12. The statutory deadline is seven months after the close of the financial year (art. 3:10 par. 1 CAC, art. 3:47 par. 7 for ASBL and foundations). Applied to the financial year that closed on 31-12-2025, that is 31-07-2026.
Deadline per financial year
Year closed Due by Filed Variance Reference
31-12-2025 31-07-2026 09-07-2026 22 d early 2026-00276862
31-12-2024 31-07-2025 21-08-2025 21 d late 2025-00391424
31-12-2023 31-07-2024 26-06-2024 35 d early 2024-00175580

Source: the National Bank's deposit records, as we have ingested them. NOTE: our copy has a gap across June to August 2026, missing roughly 220,000 deposits; for July we hold 15,605 of about 137,000 expected. A year whose deadline falls in that window shows as not confirmed, not as not filed. Filing late covers nearly half the market and is therefore not scored; only not filing, being more than 90 days late and breaking a punctual record carry weight.

Directors

9 directors
Current directors & mandates
  • JCO Consulting SRLLegal entity
    Director· perm. rep.: Jean Combalbert
    State Gazette act 25086684 (09-07-2025)
    Current
    14-04-2025 → present
  • QBIC VENTURE PARTNERS IIIPublic limited company
    Director· perm. rep.: Sara VANDENWIJNGAERT
    State Gazette act 24065353 (23-04-2024)
    Current
    04-09-2023 → present
  • ALLAER Didier Georges Jean-Marie
    Director
    State Gazette act 22350205 (03-08-2022)
    Current
    03-08-2022 → present
  • NOSHAQ PARTNERSPrivate limited company
    Director· perm. rep.: LIMBOURG Marleen Johanna
    State Gazette act 22350205 (03-08-2022)
    Current
    03-08-2022 → present
  • R&D CLOSEPrivate limited company
    Director· perm. rep.: CLOSE Pierre
    State Gazette act 22350205 (03-08-2022)
    Current
    03-08-2022 → present
  • RAPINO ManagementPrivate limited company
    Director· perm. rep.: RAPINO Francesca
    State Gazette act 22350205 (03-08-2022)
    Current
    03-08-2022 → present
Show 3 more sitting directors
  • Sara VANDENWIJNGAERT
    Director
    State Gazette act 22350205 (03-08-2022)
    Current
    03-08-2022 → present
  • VENTURE COACHINGPrivate limited company
    Director· perm. rep.: MATTIVI Didier Jean-Marie Joseph
    State Gazette act 22350205 (03-08-2022)
    Current
    03-08-2022 → present
  • ZABEAU Marcus Florent Oscar
    Director
    State Gazette act 22350205 (03-08-2022)
    Current
    03-08-2022 → present

Structure & network

Connections & network

9 connected companies
AILOS, Shared corporate director AAILOSAMPACIMON, Shared corporate director AAMPACIMONBridge2Health, Shared corporate director BBridge2HealthCryoport Belgium, Shared corporate director CBCryoportBelgiumNETWORK RESEARCH BELGIUM, Shared corporate director NRNETWORKRESEARCH…LGIUMNOMICS, Shared corporate director NNOMICSTHERAtRAME THERAtRAME0786.448.581
Shared directors
Network connections
AILOS
Shared corporate director
AMPACIMON
Shared corporate director
Bridge2Health
Shared corporate director
Cryoport Belgium
Shared corporate director
Show 2 more network connections
NETWORK RESEARCH BELGIUM
Shared corporate director
NOMICS
Shared corporate director
3 further connected companies in this network. Available in Kantoor S. See plans →

Ownership & control

5 parties
Control over this companysits on this company's board5
61 subsidiaries · 1 location
7 subsidiaries
4 subsidiaries · 2 locations
1 subsidiary
1 subsidiary
controls
THERAtRAMEBE 0786.448.581

Locations & real estate

Registered office

Cannot be placed on the map

This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.

Avenue de l'Hôpital 14000 Liège

Establishment units

1 location
THERATRAME
Avenue de l'Hôpital 1, 4000 LiègeScientific research and development
since 20222.350.127.579
Parcels1
Ground area1.4 ha
Buildings1
Building footprint2.3 ha
Volume (LiDAR)538,905 m³
Tallest building48.9 m · ±8 fl.

Real-estate footprint

Wallonia 1 (100%)
Parcel (capakey) Region Area Buildings Height / fl.
62826D0504/00R002
ProtectedMonument
Wallonia 1.4 ha 1 · 2.3 ha 48.9 m · 8 fl.
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
1 of these parcels carry protected heritage (source: regional heritage registers, Onroerend Erfgoed / patrimoine.brussels).

Similar

Similar companies

Comparable size, same sector

Company registry

Company registry (CBE)

Crossroads Bank
Activities
Research and development on biotechnology72101Scientific research and development72200Other research and development on natural sciences72109